Hystelica

08/01/2026

05/01/2026

In 2026, Hystelica will open more real live and in-person for our community of women to gather together, share in our embodiment, exploration, research, and experience.

We are excited to annonce that this spring, Hystelica joins Entheo for a women-centred retreat grounded in science, embodiment, and deep nervous system care. Designed for those working with, or curious about, the intersection of female biology, altered states, and healing, this retreat brings together research, ritual, and rest in a carefully held environment.

Across the retreat, we’ll explore how living in a female body shapes experience across the lifespan, supported by breathwork, movement, integration practices, and community connection. This is an opportunity to step out of the cognitive and into the embodied, while remaining anchored in evidence, safety, and thoughtful facilitation.

📍 April 24-29, 2026

📍 The Place to Be, Netherlands
Led by Lucyne Pearson, Dr. Grace Blest Hopley, and Lana Porter
See our website for more information ✨

19/12/2025

16/12/2025

Women’s mental health is dynamic, shaped by neurobiology, hormones, and context.
If psychedelics are to become part of evidence-based psychiatry, they must be studied through a s*x- and gender-informed lens from the start.

13/12/2025

A recent proof-of-principle study explored M**A-assisted therapy as an experience-dependent intervention rather than a conventional pharmacological treatment. Two M**A sessions combined with structured psychotherapy were associated with marked reductions in depressive symptoms and functional impairment at follow-up.
While limited by its open-label design, these findings support further randomized controlled trials and contribute to an emerging shift in psychiatry: from chronic symptom modulation toward time-limited, psychotherapy-facilitating interventions.
Br J Psychiatry, 2025

13/12/2025

Major depressive disorder remains difficult to treat for a substantial proportion of patients.
A recent proof-of-principle study explored M**A-assisted therapy as an experience-dependent intervention rather than a conventional pharmacological treatment. Two M**A sessions combined with structured psychotherapy were associated with marked reductions in depressive symptoms and functional impairment at follow-up.
While limited by its open-label design, these findings support further randomized controlled trials and contribute to an emerging shift in psychiatry: from chronic symptom modulation toward time-limited, psychotherapy-facilitating interventions.
Br J Psychiatry, 2025

03/12/2025

The International Day of Persons with Disabilities is a reminder that accessibility must be embedded into new medical developments. As the evidence base for psychedelic therapies continues to grow, it is very important that people with disabilities are not systematically excluded from clinical trials or overlooked in the development of future treatment guidelines.

As psychedelic interventions move closer to regulated clinical practice, considerations of equity become even more urgent. Disabled communities already face significant structural and financial barriers to care. Ensuring that emerging treatments are accessible, inclusive, and responsive to diverse needs is an essential step toward ethical and compassionate mental-health care.